Discusses FDA Approval of Furoscix ReadyFlow for IV-Equivalent Diuretic Therapy in Fluid Overload July 24, 2026 9:00 ...
Raises 2026 Core FFO per share guidance. Announces portfolio realignment through planned 2026 dispositions of $1.5-$2.0 billion. LOS ANGELES, July 23, 2026 /PRNewswire/ -- Rexford ...
Raises 2026 Core FFO per share guidance Announces portfolio realignment through planned 2026 dispositions of $1.5-$2.0 ...